Cell Reports Medicine, Volume *5*

Supplemental information

Activation of hepatic adenosine A1 receptor ameliorates MASH via inhibiting SREBPs maturation

Weize Zhu, Ying Hong, Zhaowei Tong, Xiaofang He, Yan Li, Hao Wang, Xinxin Gao, Pengtao Song, Xianshan Zhang, Xiaochang Wu, Zhenhua Tan, Wenjin Huang, Zekun Liu, Yiyang Bao, Junli Ma, Ningning Zheng, Cen Xie, Xisong Ke, Wen Zhou, Wei Jia, Mingxiao Li, Jing Zhong, Lili Sheng, and Houkai Li

Activation of hepatic adenosine A1 receptor ameliorates MASH via inhibiting SREBPs maturation

Supplementary Figures

Fig S1



Fig. S1. Liver-specific A_1R deletion exaggerates MAFL/MASH in mice. Related to Figure 1.
(**A**) Schematic showing the CRISPR-Cas9 technology targeting *A_1R* to generate liver-specific knockout mice (LKO). (**B**) Agarose gel electrophoresis of qPCR amplification products from the mice with

various genotypes. (**C**) Hepatic A_1R mRNA expression from the Flox and LKO mice. (*n*=3) (**D**) The hepatocytes membrane proteins expression of adenosine receptor subtypes, including A_1R, $A_{2A}R$, $A_{2B}R$, and A_3R. Flox and LKO mice were fed with normal chow diet (ND) for 16 weeks (*n*=6). ATP1A1 was used as cytomembrane protein control. (**E**) Diagram of experimental design. (**F**) Body weight. (**G**) Serum ALT and AST. (**H**) the representative image of liver H&E staining. (**I**) Quantification of hepatic TG. (**J**) Blood glucose levels during ipGTT and corresponding AUC encompassing 120 min of ipGTT. (**K**) Relative protein expression of CPT1α, CD36, FASN, and ACC. GAPDH functioned as a reference protein. (**L** to **T**) Flox and LKO mice were fed with HFD for 16 weeks (*n*=5-6). (**L**) Body weight gain. (**M**) Serum total cholesterol. (**N**) Liver index (**O**) Fasting blood glucose level. (**P**) Fasting serum insulin level. (**Q**) HOMA-IR. (**R-S**) Blood glucose levels during ipGTT or ipITT and corresponding AUC. (**T**) Hepatic inflammatory cytokines including IL-1β, IL-6, and TNF-α. (**U-W**) Flox mice and LKO mice were fed a calorie-restricted HFD (CD-HFD) for 9 weeks (**U**) Immunofluorescence of CD11b in the liver of Flox and LKO mice. (*n*=3-4) (**V**) Serum inflammation cytokines including IL-1β, IL-6, and TNF-α. (*n*=5-6) (**W**) Relative protein expression of TGF-β, pSmad2, smad2. (*n*=6) (**X**) The enrichment of ^{13}C label incorporation into hepatic fatty acids were examined by LC-MS in Flox and LKO mice fed an AMLN diet for 7 days, fasted from 9 a.m. to 7 p.m., refed for 2 hours, and force-fed ^{13}C-fructose (*n*=6). Results are representative of 1 biological replicate. Data are depicted as mean ± SEM. Student's unpaired *t*-test; *$p<0.05$, **$p<0.01$.



1

2 **Fig. S2. Liver-specific A$_1$R overexpression protects mice from diet-induced NAFL/MASH.**

3 **Related to Figure 2.**

4 (**A-I**) C57BL/6J mice were inoculated with Vehicle-AAV (Vehicle) or *A$_1$R*-overexpression-AAV (A$_1$R

5 $^{\text{Liver OE}}$) intravenously, and then were fed with HFD for 12 weeks (*n*=5~9). AAV, adeno-associated virus.

6 (**A**) Schematic representation of construct AAV-mediated *A$_1$R* overexpression mice, with A$_1$R protein

7 expression in cell membrane of hepatocytes and *Adora1* mRNA level. (**B**) Body weight gain. (**C**)

8 Serum total cholesterol. (**D**) Liver index. (**E**) Fasting blood glucose level and (**F**) fasting serum insulin

level. (n=5) (**G**) HOMA-IR. (**H**) Blood glucose levels during ipGTT or ipITT and corresponding AUC. (**I**) Hepatic inflammatory cytokines including IL-1β, IL-6, and TNF-α. **(J-N)** LKO mice were inoculated with Vehicle-AAV ($LKO^{Vehicle}$) or A_1R-overexpression-AAV (LKO^{Res}) intravenously, and then were fed with HFD for 16 weeks (n=3). (**J**) Diagram of experimental design, and A_1R protein expression in hepatic membrane. (**K**) The representative image of liver H&E staining. (**L**) Body weight. (**M**) Quantification of hepatic triglycerides (TG). (**N**) Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST). (**O-R**) Vehicle or A_1R-overexpression-AAV ($A_1R^{\text{Liver OE}}$) intravenously at 9th week during 16 weeks HFD fed (n=6). (**O**) Diagram of experimental design. (**P**) The representative image of liver H&E staining, with hepatic steatosis score. (**Q**) Quantification of hepatic TG. (**R**) Relative protein expression of FASN, and ACC. (**S-T**) Vehicle mice and $A_1R^{\text{Liver OE}}$ mice were fed a CD-HFD for 9 weeks. (**S**) Immunofluorescence of CD11b in the liver of $A1R^{\text{Liver OE}}$ mice. (n=5) (**T**) Relative protein expression of TGF-β, pSmad2, smad2. (**U-Z**) Vehicle or $A_1R^{\text{Liver OE}}$ was intravenously injected at 13th week of the 28 weeks HFD feeding (n=8-10). (**U**) Diagram of experimental design. (**V**) Representative micrographs of liver, hepatic staining of H&E and Sirius red, along with Hepatic steatosis scores and NAS scores. (**W**) Body weight. (**X**) Liver weight and Quantification of hepatic TG. (**Y**) Serum TC level. (**Z**) Serum ALT, AST, and ALP. ATP1A1 was used as cytomembrane protein control. TUBULIN or GAPDH was used as total protein control. Results are representative of 1 biological replicate. Data are depicted as mean ± SEM. Student's unpaired t-test, One-way ANOVA analysis.; *$p<0.05$, **$p<0.01$.



1

2 **Fig. S3. A₁R controls the maturation of SREBPs via PKAc. Related to Figure 3.**

3 (**A**) AML-12 cells were treated with CPA (A₁R activator, 1 μM, 48 h), DbcAMP (PKA activator, 200

4 μM, 12 h), DPCPX (A₁R inhibitor, 1 μM, 48 h), H89 (PKA inhibitor, 20 μM, 4 h), co-treated with CPA

5 and DbcAMP, or co-treated with DPCPX and H89, respectively. nSREBP1c and nSREBP2 protein

6 expression are shown. LAMIN B was used as nuclear protein control. (*n*=3) **(B)** AML-12 cells were

7 treated with DPCPX (A₁R inhibitor, 1 μM, 48 h), H89 (PKA inhibitor, 20 μM, 4 h), or co-treated with

8 DPCPX and H89, respectively. Fluorescent staining of SREBP1c or SREBP2 (red) in each group was

9 performed. The nuclei were stained by hoechst (blue). **(C-J)** HFD-fed Flox and LKO mice were treated

10 with or without H89 (i.p., 1 mg/kg body weight) daily for 8 weeks (*n*=5-6). (**C**) Diagram of

11 experimental design. (**D**) The representative image of liver H&E and Oil red O staining, with hepatic

1 steatosis score. (**E**) Body weight. (**F**) Quantification of hepatic TG. (**G)** Serum ALT level. (**H**) Serum
2 TG level. (**I**) Serum TC and LDL-C level. (**J**) Protein expression of nSREBP1c. LAMIN B1 was used
3 as nuclear protein control. Results are representative of 1 biological replicate. Data are depicted as
4 mean ± SEM. One-way ANOVA analysis; $^*p<0.05$, $^{**}p<0.01$.

Fig S4



Fig. S4. A$_1$R activation accelerates SCAP protein degradation and hepatic A$_1$R expression is upgraded in MAFLD patients and mouse models. Related to Figure 3-6.
(A) Protein expression of INSIG1, S1P and S2P in liver of A$_1$R $^{\text{Liver OE}}$ (*n*=5-10) or LKO (*n*=6) mice. (**B**) Co-immunoprecipitation (co-IP) of PKAc with SCAP were performed in the AML-12 cells treated with DPCPX (1 μM) or CPA (1 μM) for 48 h. (**C**) Protein expression of SCAP in the AML-12 cells treated with H89 (20 μM, 4 h) or DbcAMP (200 μM, 12h) in the presence of cycloheximide (CHX, 50 μM) for 0, 2, 4, 8 h. GAPDH was used as total protein control. (*n*=3) **(D)** Gene and mRNA expression

of A_1R in liver of patient with MAFLD in public data (GSE89632, GSE135251). **(E-F)** A_1R protein expression in hepatocellular membrane of mice. (*n*=3-6) **(G)** mRNA expression of ARs in liver of mice. (*n*=3) ATP1A1 was used as cytomembrane protein control. (**H**) PKA-dependent phosphorylated targets in response to A_1R suppression. (Localization probability > 0.75; score diff >5 and score > 60). Results are representative of 1 biological replicate. Data are depicted as mean ± SEM. Student's unpaired *t*-test (A, D, F), One-way ANOVA analysis (G); $*p<0.05$, $**p<0.01$.



Figure S5. A_1R pharmacological activation inhibits diet-induced MAFL and MASH in mice. Related to Figure 7.

(**A** to **K**) C57BL/6J mice were fed a HFD for 16 weeks, and injected intraperitoneally 0.9% NaCl solution (NAFL) or 1 mg/kg 2-Chloro-N6-cyclopentyladenosine (CCPA) daily from 9th week. (*n*=8) (**A**) Diagram of experimental design. (**B**) Representative image of epididymis adipose, liver and liver staining of H&E and Oil red O, with hepatic steatosis scores. (**C**) Body weight and liver weight. (**D**) Energy intake (energy intake was record every week from 9th to 16th week, n=8 per group) (**E**) Quantification of hepatic TG. (**F**) Serum TC (**G**) Serum ALT. (**H**) Fasting blood glucose, serum insulin,

1 and HOMA-IR. (**I**) Blood glucose levels during ipGTT and corresponding AUC encompassing 120
2 min. (**J**) ELISA detection of active PKAc level. (**K**) Relative protein expression of PKAc, SCAP,
3 SREBPs (flSREBP1c, flSREBP2, nSREBP1c, nSREBP2), and SREBP regulated proteins (FASN,
4 ACC). GAPDH was used as total protein control, LAMIN B1 was used as nuclear protein control. (**L**
5 to **Q**) C57BL/6J mice were fed a normal chow diet (Con) or CD-HFD for 9 weeks, during the process,
6 CD-HFD mice were divided into 2 subgroups, and injected intraperitoneally 0.9% NaCl solution (CD-
7 HFD) or 1 mg/kg CCPA daily from week 4. (n=8) (**L**) Diagram of experimental design. (**M**) H&E and
8 Sirius red staining of liver sections, with histological evaluation. (**N**) Serum ALT, AST, and ALP. (**O**)
9 Serum inflammatory cytokines including IL-1β, IL-6, and TNF-α. (**P**) mRNA expression of fibrosis-
10 related genes (*Col1a1, Col3a1, Ctgf, Timp1*) and chemokine-related genes (*Ccl2, Ccl5, Cxcl10*) in liver.
11 Results are normalized for *18S*. (**Q**) Relative protein expression of α-SMA and IκB. GAPDH was used
12 as a control. LAMIN B1 was used as nuclear protein control. Results are representative of 1 biological
13 replicate. Data are depicted as mean ± SEM. Student's unpaired *t*-test (**B** to **K**); One-way ANOVA
14 analysis (**M** to **Q**); *$p<0.05$, **$p<0.01$.
15



1

2 **Figure S6. The anti-MAFLD test of Adenosine, and the screening and identification of A_1R**

3 **activators. Related to Figure 7.**

4 (**A** to **F**) C57BL/6J mice were fed a HFD for 18 weeks, and injected intraperitoneally 0.9% NaCl

5 solution (NAFL) , 10mg/kg adenosine or 1 mg/kg 2-Chloro-N6-cyclopentyladenosine (CCPA) daily

6 from 12th week. (*n*=5-6) (**A**) Diagram of experimental design. (**B**) Representative image of liver. (**C**)

7 Hepatic steatosis score. (**D**) Liver weight. (**E**) Quantification of hepatic triglycerides (TG). (**F**) Liver

8 injury indicators including serum alanine aminotransferase (ALT) and aspartate aminotransferase

9 (AST). Results are representative of 1 biological replicate. Data are depicted as mean ± SEM. One-way

1 ANOVA analysis; *n*=5-6, *$p<0.05$, **$p<0.01$. (**G** to **N**) **The screening and identification of A_1R**
2 **activators.** (**G-H**) AML-12 cells were treated with 0.5, 1, 2 μM timosaponin AIII (TA3) for 48 h in the
3 presence of glycerol (20 mM) and glucose (4.5 g/L) (Model). Representative micrographs and the
4 quantification of Oil Red O staining. Relative TG and cAMP level. (**I**) Cellular TG level in the primary
5 hepatocytes (PH) from WT or LKO mice treated with 0.5, 1, 5, 10 μM TA3 for 48 h in the presence of
6 glycerol (20 mM) and glucose (4.5 g/L) (Model). (**J**) Cellular TG level in HepG2 cells treated with 0.5,
7 1, 2 μM TA3 in model. (**K**) Relative protein expression of PKAc, SREBPs (flSREBP1c, flSREBP2,
8 nSREBP1c, nSREBP2), and SREBP regulated proteins (FASN, ACC). (**L**) Cellular TG level. (**M**)
9 Relative protein expression of FASN and ACC. (**N**) Cellular TG level. β-TUBULIN was used as total
10 protein control; LAMIN B1 was used as nuclear protein control. Results are representative of 1
11 biological replicate, *n*=3. Data are depicted as mean ± SEM. One-way ANOVA analysis. *$p<0.05$,
12 **$p<0.01$.
13



Figure S7. Timosaponin AIII inhibits diet-induced MAFL and MASH in mice in an A$_1$R-dependent manner. Related to Figure 7.

(**A** to **D**) C57BL/6J mice were fed with HFD for 16 weeks, and injected intraperitoneally 0.9% NaCl solution (HFD) or 5,10 mg/kg timosaponin AIII (TA3) daily from 9th week. (n=7-10) (**A**) Body weight. (**B**) Representative image of liver. (**C**) Serum TC. (**D**) Serum ALT and AST. (**E** to **F**) C57BL/6J mice were fed a normal chow diet (NCD, Con) or CD-HFD for 9 weeks, during the process, CD-HFD mice

1 were divided into 3 subgroups, and injected intraperitoneally with 0.9% NaCl solution (CD-HFD) or 5,
2 10 mg/kg TA3 daily from 4th week. (*n*=6-8) (**E**) Representative image of liver. (**F**) mRNA expression of
3 fibrosis-related genes (*Col1a1, Col3a1, Ctgf, Tgfb*), proinflammatory-related genes (*Tnfα*), and
4 chemokine-related genes (*Ccl2, Ccl5, Cxcl2, Cxcl10*) in liver of CD-HFD mice. (**G** to **L**) LKO mice
5 were fed a normal chow diet or CD-HFD for 9 weeks, CD-HFD mice were injected intraperitoneally
6 with 0.9% NaCl solution (MASH), 1 mg/kg 2-Chloro-N6-cyclopentyladenosine (CCPA) or 10 mg/kg
7 TA3 daily from 4th week. (n=5) (**G**) Diagram of experimental design. (**H**) Representative image of
8 Liver and hepatic H&E staining. (**I**) Histological evaluation. (**J**)Serum ALT, AST, and ALP. (**K**) Serum
9 inflammatory cytokines. (**L**) Relative protein expression of α-SMA and IκB. GAPDH was used as total
10 protein control. Results are representative of 1 biological replicate. Data are depicted as mean ± SEM.
11 One-way ANOVA analysis; *p<0.05, **p<0.01. Results are normalized for *18S*. Results are
12 representative of 1 biological replicate. Data are depicted as mean ± SEM. One-way ANOVA analysis;
13 *$p<0.05$, **$p<0.01$.
14

Table S1. Clinical and biochemical characteristics of the patients with biopsy proven MAFLD. Related to Figure 6.

Characteristics	All (*n*=30)	MAFL (*n*=22)	Control (*n*=8)	*p* value
Demographics				
Age (years)	51.3±2.2	52.7±2.4	47.6±3.9	0.3116
Gender, n (%)				
Female	20 (64.1)	14 (63.6)	6 (75.0)	
Male	10 (35.9)	8 (36.4)	2 (25.0)	
BMI (kg/m^2)	22.1±0.7	22.5±0.9	20.9±0.6	0.3242
Biological data				
AST (U/L)	55.4±14.3	48.7±13.2	72.0±39.0	0.4719
ALT (U/L)	86.4±27.6	65.5±18.7	138.6±85.7	0.2386
Triglycerides (mmol/L)	1.61±0.26	1.90±0.34	0.96±0.17	0.0894
Total cholesterol (mmol/L)	4.08±0.21	4.23±0.26	3.75±0.37	0.3030
Glucose (mmol/L)	6.75±0.60	6.58±0.72	7.25±1.12	0.6361
Histology				
NAS, n (%)				
Steatosis				
0	8 (26.7)	0 (0.0)	8 (100.0)	
1	9 (30.0)	9 (40.9)	0 (0.0)	
2	10 (33.3)	10 (45.5)	0 (0.0)	
3	3 (10.0)	3 (13.6)	0 (0.0)	
Ballooning				
0	16 (53.3)	8 (36.4)	8 (100.0)	
1	14 (46.7)	14 (63.6)	0 (0.0)	
2	0 (0.0)	0 (0.0)	0 (0.0)	
Lobular Inflammation				
0	23 (76.7)	15 (68.2)	8 (100.0)	
1	7 (23.3)	7 (31.8)	0 (0.0)	
2	0 (0.0)	0 (0.0)	0 (0.0)	
3	0 (0.0)	0 (0.0)	0 (0.0)	
Fibrosis stage				
F0	30 (100.0)	22 (100.0)	8 (100.0)	
F1	0 (0.0)	0 (0.0)	0 (0.0)	
F2	0 (0.0)	0 (0.0)	0 (0.0)	
F3	0 (0.0)	0 (0.0)	0 (0.0)	
F4	0 (0.0)	0 (0.0)	0 (0.0)	
Clinical diagnose				
Hepatic hemangioma	15 (50.0)	12 (54.5)	3 (37.5)	
Liver traumatic rupture	7 (23.3)	2 (9.1)	5 (62.5)	
Hepatolithiasis	8 (26.7)	8 (36.4)	0 (0.0)	

1 Data are presented as mean ± SEM. *P* values were obtained using Student's *t*-test for continuous
2 variables.

Table S2. Clinical and biochemical characteristics of the patients with biopsy proven MASH. Related to Figure 1.

Characteristics	All (*n*=13)	MASH (*n*=9)	Control (*n*=4)	*p* value
Demographics				
Age (years)	44.6±2.7	40.9±2.8	53.0±3.3	0.0287
Gender, n (%)				
Female	6 (46.2)	3 (33.3)	3(75.0)	
Male	7 (53.8)	6 (66.6)	1 (25.0)	
BMI (kg/m^2)	27.0±1.3	29.4±1.0	21.5±1.4	0.0007
Biological data				
AST (U/L)	62.6±10.6	70.8.0±12.5	44.3±19.3	0.2672
ALT (U/L)	99.5±19.1	126.3±20.8	39.2±19.6	0.0275
Triglycerides (mmol/L)	1.94±0.33	2.34±0.40	1.03±0.24	0.0631
Total cholesterol (mmol/L)	4.93±0.21	4.84±0.27	5.12±0.33	0.5499
Glucose (mmol/L)	5.45±0.27	5.62±0.38	5.06±0.14	0.3644
Histology				
NAS, n (%)				
Steatosis				
0	4 (30.8)	0 (0.0)	4 (100.0)	
1	2 (15.4)	2 (22.2)	0 (0.0)	
2	2 (15.4)	2 (22.2)	0 (0.0)	
3	5 (38.5)	5 (55.6)	0 (0.0)	
Ballooning				
0	4 (30.8)	0 (0.0)	4 (100)	
1	3 (23.1)	3 (33.3)	0 (0.0)	
2	6 (46.1)	6 (66.6)	0 (0.0)	
Lobular Inflammation				
0	4 (30.8)	0 (0.0)	4 (100)	
1	4 (30.8)	4 (44.4)	0 (0.0)	
2	2 (15.9)	2 (22.2)	0 (0.0)	
3	3 (23.1)	3 (33.3)	0 (0.0)	
Fibrosis stage				
F0	4 (30.8)	0 (0.0)	4 (100.0)	
F1	1 (7.7)	1 (11.1)	0 (0.0)	
F2	6 (46.1)	6 (66.7)	0 (0.0)	
F3	2 (15.4)	2 (22.2)	0 (0.0)	
F4	0 (0.0)	0 (0.0)	0 (0.0)	
Clinical diagnose				
MASH	9 (69.2)	9 (100.0)	0 (0.0)	
Hepatic hemangioma	3 (23.1)	0 (0.0)	3 (75.0)	
Hepatolithiasis	1 (7.7)	0 (0.0)	1 (25.0)	

1 Data are presented as mean ± SEM. *P* values were obtained using Student's *t*-test for continuous
2 variables.

1 **Table S3. Primers(mice) for qPCR.**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Oligonucleotides		
18s forward: 5'-CCATCCAATCGGTAGTAGCG -3'	This paper	N/A
18s reverse: 5'-GTAACCCGTTGAACCCCATT-3'	This paper	N/A
A_1R forward: 5'-TGTGCCCGGAAATGTACTGG- 3'	This paper	N/A
A_1R reverse: 5'-TCTGTGGCCCAATGTTGATAAG-3'	This paper	N/A
Ccl2 forward: 5'-TACAAGAGGATCACCAGCAGC-3'	This paper	N/A
Ccl2 reverse: 5'-ACCTTAGGGCAGATGCAGTT-3'	This paper	N/A
Ccl5 forward: 5'-TGCTGCTTTGCCTACCTCTC-3'	This paper	N/A
Ccl5 reverse: 5'-TCTTCTCTGGGTTGGCACAC-3'	This paper	N/A
Cxcl10 forward: 5'-ATGACGGGCCAGTGAGAATG-3'	This paper	N/A
Cxcl10 reverse: 5'-ATGATCTCAACACGTGGGCA-3'	This paper	N/A
Cxcl2 forward: 5'-GCGCCCAGACAGAAGTCATA-3'	This paper	N/A
Cxcl2 reverse: 5'-CAGTTAGCCTTGCCTTTGTTCA-3'	This paper	N/A
Il6 forward: 5'-TAGTCCTTCCTACCCCAATTTCC-3'	This paper	N/A
Il6 reverse: 5'-TTGGTCCTTAGCCACTCCTTC-3'	This paper	N/A
Il1β forward: 5'-CCGTGGACCTTCCAGGATGA-3'	This paper	N/A
Il1β reverse: 5'-GGGAACGTCACACACCAGCA-3'	This paper	N/A
Tnfα forward: 5'-CATCTTCTCAAAATTCGAGTGACAA-3'	This paper	N/A
Tnfα reverse: 5'-TGGGAGTAGACAAGGTACAACCC-3'	This paper	N/A
Col1a1 forward: 5'-TGCTAACGTGGTTCGTGACCGT-3'	This paper	N/A
Col1a1 reverse: 5'-ACATCTTGAGGTCGCGGCATGT-3'	This paper	N/A
Col3a1 forward: 5'-ACGTAAGCACTGGTGGACAG-3'	This paper	N/A
Col3a1 reverse: 5'-CCGGCTGGAAAGAAGTCTGA-3'	This paper	N/A
Ctgf forward: 5'-TGACCCCTGCGACCCACA-3'	This paper	N/A
Ctgf reverse: 5'-TACACCGACCCACCGAAGACACAG-3'	This paper	N/A
Timp1 forward: 5'-GAGACCACCTTATACCAGCGTT-3'	This paper	N/A
Timp1 reverse: 5'-TACGCCAGGGAACCAAGAAG-3'	This paper	N/A
Actb forward: 5'-GTGACGTTGACATCCGTAAAGA-3'	This paper	N/A
Actb reverse: 5'-GCCGGACTCATCGTACTCC-3'	This paper	N/A

2